A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line

Molecular Pharmaceutics

Volumn 5, Issue 2, 2008, Pages 280-286

  Tagne, Jean Bosco ^a   Kakumanu, Srikanth ^a   Ortiz, Daniela ^a   Shea, Thomas ^a   Nicolosi, Robert J ^a  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

Apoptosis; Breast cancer; Cell proliferation; Nano emulsion; Tamoxifen

Indexed keywords

TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; EMULSION; HUMAN; HUMAN CELL; LIPID SOLUBILITY; MICROEMULSION; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUSPENSION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; FEMALE; HUMANS; MICE; NANOPARTICLES; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42549145145     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp700091j     Document Type: Article

References (50)

1. Jemal, A.; et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55 (1), 10-30.
2. Guarneri, V.; Conte, P. F. The curability of breast cancer and the treatment of advanced disease. Eur. J. Nucl. Med. Mol. Imaging 2004, 31 (1), S149-61.
3. Murphy, M. J., Jr. Molecular Action and Clinical Relevance of Aromatase Inhibitors. Oncologist 1998, 3 (2), 129-130.
4. Kallio, A. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005, 10 (6), 1395-410.
5. Lim, Y. C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 2005, 55 (5), 471-8.
6. Steiner, A. Z.; Terplan, M.; Paulson, R. J. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum. Reprod. 2005, 20 (6), 1511-5.
7. Eugster, E. A. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J. Pediatr. Endocrinol. Metab. 1999, 12 (5), 681-6.
8. Eugster, E. A. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J. Pediatr. 2003, 143 (1), 60-6.
9. Rabinow, B. E. Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 2004, 3 (9), 785-96.
10. Jiao, J.; Rhodes, D. G.; Burgess, D. J. Multiple emulsion stability: pressure balance and interfacial film strength. J. Colloid Interface Sci. 2002, 250 (2), 444-50.
11. Sonneville-Aubrun, O.; Simonnet, J. T.; L'Alloret, F. Nanoemulsions: a new vehicle for skincare products. Adv. Colloid Interface Sci. 2004, 108-109, 145-9.
12. Sadurni, N. Studies on the formation of O/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur. J. Pharm. Sci. 2005, 26 (5), 438-45.
13. Tadros, T. Formation and stability of nano-emulsions. Adv. Colloid Interface Sci. 2004, 108-109, 303-18.
14. Constantinides, P. P.; Tustian, A.; Kessler, D. R. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev. 2004, 56 (9), 1243-55.
15. Kumar, R. Supramolecular assemblies based on copolymers of PEG600 and functionalized aromatic diesters for drug delivery applications. J. Am. Chem. Soc. 2004, 126 (34), 10640-4.
16. Cavalli, R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int. J. Pharm. 1999, 182 (1), 59-69.
17. Attivi, D. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev. Ind. Pharm. 2005, 31 (2), 179-89.
18. Merisko-Liversidge, E.; McGurk, S. L.; Liversidge, G. G. Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm. Res. 2004, 21 (9), 1545-53.
19. Pan, Y. Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres. Acta Pharmacol. Sin. 2002, 23 (11), 1051-6.
20. Vila, A. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int. J. Pharm. 2005, 292 (1-2), 43-52.
21. Thanos, C. G. Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride. Pharm. Res. 2003, 20 (7), 1093-100.
22. Kuo, F. A nanoemulsion of an anti-oxidant synergy formulation reduces tumor growth rate in neuroblastoma-bearing nude mice. J. Exp. Ther. Oncol. 2007, 6 (2), 129-35.
23. Bange, J.; Zwick, E.; Ullrich, A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 2001, 7 (5), 548-52.
24. Taylor, I. W. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res. 1983, 43 (9), 4007-10.
25. Mizutani, A. Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res 2004, 64 (9), 3144-7.
26. Bartkova, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434 (7035), 864-70.
27. Hickman, J. A.; et al. Mechanisms of cytotoxicity caused by antitumour drugs. Toxicol. Lett. 1992, 64-65. Spec. No. p 553-61.
28. Middleton, M. R.; Margison, G. P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 2003, 4 (1), 37-44.
29. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994, 78 (4), 539-42.
30. Bustami, R. T. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. 2000, 17 (11), 1360-6.
31. Lee, J. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 2003, 92 (10), 2057-68.
32. Denmeade, S. R.; Isaacs, J. T. Programmed Cell Death (Apoptosis) and Cancer Chemotherapy. Cancer Control 1996, 3 (4), 303-309.
33. Chawla, J. S.; Amiji, M. M. Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm. 2002, 249 (1-2), 127-38.
34. Dellian, M. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 2000, 82 (9), 1513-8.
35. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50 (1), 161-77.
36. Dawson, G. F.; Halbert, G. W. The in vitro cell association of invasin coated polylactide-co-glycolide nanoparticles. Pharm. Res. 2000, 17 (11), 1420-5.
37. Redhead, H. M.; Davis, S. S.; Illum, L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Controlled Release 2001, 70 (3), 353-63.
38. Lockman, P. R. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target 2004, 12 (9-10 635), 41.
39. Yap, S. P.; Yuen, K. H. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int. J. Pharm. 2004, 281 (1-2), 67-78.
40. Lockman, P. R. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002, 28 (1), 1-13.
41. Schweizer, D. DAPI fluorescence of plant chromosomes prestained with actinomycin D. Exp. Cell Res. 1976, 102 (2), 408-13.
42. Schweizer, D.; Ambros, P.; Andrle, M. Modification of DAPI banding on human chromosomes by prestaining with a DNA-binding oligopeptide antibiotic, distamycin A. Exp. Cell Res. 1978, 111 (2), 327-32.
43. Burckhardt, G. Mechanisms of distamycin A/DAPI chromosome staining. I. Competition binding effects of nonintercalative DNA groove-binding agents in situ and in vitro. Cytogenet. Cell Genet. 1993, 62 (1), 19-25.
44. Wyllie, A. H. Apoptosis and carcinogenesis. Br. J. Cancer 1999, 80 (1), 34-7.
45. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992, 11 (2), 121-39.
46. da Silva, C. P. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol. 1996, 51 (10), 1331-40.
47. Nishio, K.; Arioka, H.; Saijo, N. Apoptosis and chemosensitivity. Gan To Kagaku Ryoho 1997, 24 (2), 216-21.
48. Davidoff, A. N.; Mendelow, B. V. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp. Hematol. 1993, 21 (7), 922-7.
49. Fukuda, M.; Saijo, N. Anticancer agents and apoptosis. Gan To Kagaku Ryoho 1994, 21 (3), 330-5.
50. Polkowski, K.; Skierski, J. S.; Mazurek, A. P. Anticancer activity of genistein-piperazine complex. In vitro study with HL-60 cells. Acta Pol. Pharm. 2000, 57 (3), 223-32.